Novartis has announced, first of its kind Phase III data showing Cosentyx® (secukinumab) delivered high and long-lasting skin clearance in patients with moderate-to-s...

Cells can be programmed like a computer to fight cancer, influenza, and other serious conditions - thanks to a breakthrough in synthetic biology by the University of ...

Scientists at the University of Southampton have made a significant discovery in efforts to develop a vaccine against Zika, dengue and Hepatitis C viruses that affect...

Saturday, 9 September, 14:45 to 16:15, Granada Auditorium, IFEMA Biosimilars are a much-needed and timely opportunity for physicians, patients and healthcare systems....

Eslicarbazepine acetate data shows seizure freedom in 41.3% of patients at 12 months, and retention rates of 73.4%.1 Results from the Euro-Esli study will be pre...

AMAL,  the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the first tranche of its Series B financin...

Lugano, Madrid. 1 September 2017 -- An updated version of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) will enable users ...

Cloud-based Clinical Data Suite helps Transform the Speed and Delivery of Clinical Trials HORSHAM, UK — August 30, 2017 – Cmed today announced its one-year anniversar...